Literature DB >> 14690537

Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation.

Thomas Dehmer1, Michael T Heneka, Magdalena Sastre, Johannes Dichgans, Jörg B Schulz.   

Abstract

Inflammation has been implicated in the pathogenesis of Parkinson's disease (PD). In the chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD, inducible NO synthase (iNOS) derived nitric oxide (NO) is an important mediator of dopaminergic cell death. Ligands of the peroxisome proliferator-activated receptor (PPAR) exert anti-inflammatory effects. We here investigated whether pioglitazone, a PPARgamma agonist, protected mice from MPTP-induced dopaminergic cell loss, glial activation, and loss of catecholamines in the striatum. As shown by western blot, PPARgamma was expressed in the striatum and the substantia nigra of vehicle- and MPTP-treated mice. Oral administration of 20 mg/(kg day) of pioglitazone protected tyrosine hydroxylase (TH)-positive substantia nigra neurons from death induced by 5 x 30 mg/kg MPTP. However, the decrease of dopamine in the striatum was only partially prevented. In mice treated with pioglitazone, there were a reduced activation of microglia, reduced induction of iNOS-positive cells and less glial fibrillary acidic protein positive cells in both striatum and substantia nigra pars compacta. In addition, treatment with pioglitazone almost completely blocked staining of TH-positive neurons for nitrotyrosine, a marker of NO-mediated cell damage. Because an increase in inhibitory protein-kappa-Balpha (IkappaBalpha) expression and inhibition of translocation of the nuclear factor kappaB (NFkappaB) subunit p65 to the nucleus in dopaminergic neurons, glial cells and astrocytes correlated with the protective effects of pioglitazone, our results suggest that pioglitazone sequentially acts through PPARgamma activation, IkappaBalpha induction, block of NFkappaB activation, iNOS induction and NO-mediated toxicity. In conclusion, treatment with pioglitazone may offer a treatment opportunity in PD to slow the progression of disease that is mediated by inflammation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14690537     DOI: 10.1046/j.1471-4159.2003.02210.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  125 in total

1.  Suppression of endogenous PPARγ increases vulnerability to methamphetamine-induced injury in mouse nigrostriatal dopaminergic pathway.

Authors:  Seong-Jin Yu; Mikko Airavaara; Hui Shen; Jenny Chou; Brandon K Harvey; Yun Wang
Journal:  Psychopharmacology (Berl)       Date:  2011-12-13       Impact factor: 4.530

Review 2.  Diabetes type II: a risk factor for depression-Parkinson-Alzheimer?

Authors:  Peter Riederer; Jasmin Bartl; Gerd Laux; Edna Grünblatt
Journal:  Neurotox Res       Date:  2010-06-15       Impact factor: 3.911

3.  Peroxisome proliferator activated receptor-γ and traumatic brain injury.

Authors:  Lei Qi; Asha Jacob; Ping Wang; Rongqian Wu
Journal:  Int J Clin Exp Med       Date:  2010-09-23

Review 4.  Toxicological and pathophysiological roles of reactive oxygen and nitrogen species.

Authors:  Ruth A Roberts; Robert A Smith; Stephen Safe; Csaba Szabo; Ronald B Tjalkens; Fredika M Robertson
Journal:  Toxicology       Date:  2010-07-17       Impact factor: 4.221

5.  Nurr1 and PPARγ protect PC12 cells against MPP(+) toxicity: involvement of selective genes, anti-inflammatory, ROS generation, and antimitochondrial impairment.

Authors:  Mohammad Jodeiri Farshbaf; Mahboobeh Forouzanfar; Kamran Ghaedi; Abbas Kiani-Esfahani; Maryam Peymani; Alireza Shoaraye Nejati; Tayebeh Izadi; Khadijeh Karbalaie; Maryam Noorbakhshnia; Soheila Rahgozar; Hossein Baharvand; Mohammad Hossein Nasr-Esfahani
Journal:  Mol Cell Biochem       Date:  2016-07-19       Impact factor: 3.396

Review 6.  Treatment of Radiation-Induced Cognitive Decline in Adult Brain Tumor Patients.

Authors:  Christina K Cramer; Tiffany L Cummings; Rachel N Andrews; Roy Strowd; Stephen R Rapp; Edward G Shaw; Michael D Chan; Glenn J Lesser
Journal:  Curr Treat Options Oncol       Date:  2019-04-08

Review 7.  Neurotoxins as Preclinical Models for Parkinson's Disease.

Authors:  Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2018-01-08       Impact factor: 3.911

8.  Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.

Authors:  A A Martinez; M G Morgese; A Pisanu; T Macheda; M A Paquette; A Seillier; T Cassano; A R Carta; A Giuffrida
Journal:  Neurobiol Dis       Date:  2014-12-05       Impact factor: 5.996

9.  Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors.

Authors:  Angela M Floden; Shanshan Li; Colin K Combs
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

10.  Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats.

Authors:  Sajay B Churi; Omar S Abdel-Aleem; Kiranjeet K Tumber; Heather Scuderi-Porter; Bradley K Taylor
Journal:  J Pain       Date:  2008-04-03       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.